A Phase 3 interventional study of Rifaximin (Xifaxan) and Vancomycin in Clostridium Infections and Diarrhea, sponsored by Bausch Health Americas, Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-14.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Clostridium Infections with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Clostridium Infections · United States.
Among the 121 studies in Clostridium Infections with a site in United States, this one is the 18th largest by enrollment of the 102 interventional ones that give a count, is one of 3 that started in 2005, is one of 16 in phase 3, and was the 4th registered.
251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.
Browse Clostridium Infections studies →16 of the 121 studies in Clostridium Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Healthy volunteers
Acurx Pharmaceuticals Inc. · Sites in United States
Ages 18–90
Medical College of Wisconsin · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 11 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 40 · Phase 3 21 · Phase 4 14
First in 1998; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 237 is above the median of 64 across 185 interventional studies indexed under Clostridium Infections.
Median enrollment 57 across the 102 interventional studies, 132 across the 19 observational. Of the 91 that completed or were terminated, 52 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 121 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 1 study filed under Clostridium Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Clostridium Infections with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221370Phase 3Riverside University Health System Medical CenterEnteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients | 2026-12-31 |
| NCT06237452Phase 3Vedanta Biosciences, Inc.VE303 for Prevention of Recurrent Clostridioides Difficile Infection | 2027-06 |
| NCT04305769University of VirginiaAlanyl-glutamine Supplementation for C. Difficile Treatment (ACT) | 2026-12-31 |
| NCT07250724Bactolife A/SC. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI. | 2027-01-15 |
| NCT07285213AstraZenecaPrevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | 2027-04-20 |
Add all 7 to your calendar (.ics) → With an account.
Among the 121 studies in Clostridium Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
Clostridium difficile is a bacterium that proliferates when normal colonic flora have been altered, most commonly due to antibiotic use. Clostridium difficile is non-invasive and localized to the lumen of the colon. Once established, it produces 2 potent toxins, A and B. The principal reservoir for Clostridium difficile is the hospital environment, with the risk of acquiring Clostridium difficile increasing in direct proportion to the length of hospital stay.
Patients with CDAD typically present with profuse watery or mucoid diarrhea and cramping abdominal pain. Additional symptoms include fever, nausea, anorexia, malaise, and bloody stool. More severe cases may be complicated by dehydration, electrolyte disturbances, ileus, and peritonitis. Systemic manifestations may include prerenal azotemia, sepsis syndrome, and toxic colitis. White blood cell counts (WBCs) also may be markedly elevated with a shift to immature forms. Extreme presentation of fulminant colitis may require a colectomy and even result in death. Symptoms of CDAD may begin a few days after initiation of antibiotic therapy or up to 8 weeks after its discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
rifaximin 400mg taken 3 times a day
Drug: Rifaximin (Xifaxan)
vancomycin 125mg taken 4 times a day
Drug: Vancomycin
Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.
Resolution or improvement of baseline signs and symptoms was assessed as * Absence of severe abdominal pain for 2 consecutive days at the test of cure (TOC) Visit (Day 14 +/-1); * Absence of fever (\< 38°C/100.4°F) for 2 consecutive days at the TOC Visit; and * 3 unformed (loose or watery) stools per day for at least 48 hours that was sustained through the TOC Visit.
Time frame: 14 days
Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success
Recurrence of CDAD was defined as diarrhea and a positive Clostridium difficile stool toxin assay that occurs after initial clinical success.
Time frame: 42 days
| Milestone | Rifaximin Treatment Arm | Vancomycin Comparator Arm |
|---|---|---|
| Started | 119 | 118 |
| Completed | 78 | 91 |
| Not completed | 41 | 27 |
| Withdrew: Lack of efficacy | 27 | 10 |
| Withdrew: Adverse event | 10 | 4 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Negative lab result for c. difficile | 2 | 3 |
| Withdrew: Other | 0 | 4 |
| Withdrew: Development of exclusion criteria | 0 | 1 |
Resolution or improvement of baseline signs and symptoms was assessed as * Absence of severe abdominal pain for 2 consecutive days at the test of cure (TOC) Visit (Day 14 +/-1); * Absence of fever (\< 38°C/100.4°F) for 2 consecutive days at the TOC Visit; and * 3 unformed (loose or watery) stools per day for at least 48 hours that was sustained through the TOC Visit.
| Participants | Rifaximin Treatment Arm | Vancomycin Comparator Arm |
|---|---|---|
| Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. | 67 | 73 |
Recurrence of CDAD was defined as diarrhea and a positive Clostridium difficile stool toxin assay that occurs after initial clinical success.
| Participants | Rifaximin Treatment Arm | Vancomycin Comparator Arm |
|---|---|---|
| Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success | 61 | 63 |
Collected over 42 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin Treatment Arm | — | 28/120 (23.3%) | 6/120 (5%) |
| Vancomycin Comparator Arm | — | 14/116 (12.1%) | 2/116 (1.7%) |
| Event | Rifaximin Treatment Arm | Vancomycin Comparator Arm |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 3/120 | 4/116 |
| Abdominal painGastrointestinal disorders | 4/120 | 0/116 |
| DiarrheaGastrointestinal disorders | 3/120 | 3/116 |
| Renal failure acuteRenal and urinary disorders | 3/120 | 2/116 |
| HypotensionVascular disorders | 3/120 | 2/116 |
| PneumoniaInfections and infestations | 0/120 | 2/116 |
| Mental status changesPsychiatric disorders | 0/120 | 2/116 |
| Clostridial infectionInfections and infestations | 2/120 | 1/116 |
| Clostridium colitisInfections and infestations | 2/120 | 0/116 |
| AnemiaBlood and lymphatic system disorders | 1/120 | 1/116 |
| Event | Rifaximin Treatment Arm | Vancomycin Comparator Arm |
|---|---|---|
| InsomniaPsychiatric disorders | 6/120 | 2/116 |
Modified Intent-to-Treat (MITT) population included all randomized subjects who had acute diarrhea and with a positive C. difficile stool toxin assay within ± 48 hours of screening and received at least one dose of study drug.
| Age, Continuous(years) | Rifaximin Treatment Arm | Vancomycin Comparator Arm | Total |
|---|---|---|---|
| Mean | 58.9 ± 16.22 | 60.0 ± 18.08 | 59.5 ± 17.14 |
| Sex: Female, Male(Participants) | Rifaximin Treatment Arm | Vancomycin Comparator Arm | Total |
|---|---|---|---|
| Female | 74 | 67 | 141 |
| Male | 43 | 48 | 91 |
| Race (NIH/OMB)(Participants) | Rifaximin Treatment Arm | Vancomycin Comparator Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 14 | 12 | 26 |
| White | 103 | 102 | 205 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Dec 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →